News
A consultancy’s new ranking of drug company R&D shows Eli Lilly has risen to the top of the drug development heap, while ...
Merck Animal Health will invest $895 million to expand vaccine manufacturing and R&D in Kansas, while Lilly is committing ...
StockStory.org on MSN18h
LLY Q1 Earnings Call: Revenue Beats Expectations, Profit Guidance Trimmed Amid Price PressuresGlobal pharmaceutical company Eli Lilly (NYSE:LLY) reported in Q1 CY2025, with sales up 45.2% year on year to $12.73 billion.
Eli Lilly is investing more in its home state of Indiana, pumping up to $250 million more into an existing collaboration with ...
Eli Lilly (NYSE:LLY) recently announced leadership transitions, including new roles for Ilya Yuffa, Patrik Jonsson, and ...
Eli Lilly and Company and Purdue University announced a significant expansion of their long-standing alliance, with Lilly's planned investment of up to $250 million in the collaboration over the next ...
Eli Lilly stock has been a big-time winner over ... Beyond research and development (R&D), one of the major expense items for pharmaceutical companies is the cost of raw materials for making ...
Trump's Department of Commerce is looking into what it calls national security threats from overseas drug manufacturing, and ...
Telehealth company Ro will offer single-dose vials of Eli Lilly's obesity therapy Zepbound in an expansion of the ways patients with a prescription can access the drug. The agreement means Ro has ...
These developments may fuel Eli Lilly's projected annual revenue growth of 22.7% and possibly improve its profit margins despite potential challenges like pricing pressures and rising R&D costs.
Eli Lilly (NYSE:LLY) experienced an 11% share price increase over the past month, largely influenced by the affirmation of a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results